In a recent study [20], the authors proposed a physiologically based pharmacokinetic (PBPK) model for anti-TNF therapies in adults and extrapolated the results to pregnant women, fetuses and infants with the objective to identify the best timing for the last dosing of IFX, ADA and GLM during pregnancy in IBD, and with the objective to study the recommended vaccine schedules for infants exposed to these drugs. Here, TNF is linked to inflammatory bowel disease.